Scancell Holdings PLC on Monday reported positive data from an ongoing trial on patients receiving a treatment combination for advanced melanoma, a skin cancer.

The Oxford, England-based developer of immunotherapies said the 25 patients in cohort one of a trial probing SCIB1 in combination with ipilimumab and nivolumab reached ‘the 25-week landmark point’.

These patients show 80% progression free survival, the time a patient lives without the disease getting worse, at six months with five complete responders. A complete response is when there is no evidence of cancer.

Scancell said 21 of 25 patients, 84%, have shown disease control, which is a stable disease or tumour regression.

it added that 18 out of 25 patients have shown a clinical response rate, with ‘many patients continuing to show tumour shrinkage over time’, the company said.

These results ‘compare favourably’ with outcomes from patients using ipilimumab and nivolumab alone.

‘The PFS and accumulating number of complete responders indicates that the combination of SCIB1 with double checkpoints gives sustained and durable responses which are improved when compared to double checkpoints alone,’ the company said.

Scancell’s Chief Scientific Officer Lindy Durrant added: ‘We are particularly impressed with the progression free survival data as this will be the primary endpoint of the next trial... and the key outcome for product registration. We look forward to providing further updates on our progress given the extremely positive results to date.’

Shares in Scancell were down 4.6% at 15.50 pence each in London on Monday afternoon.

Copyright 2024 Alliance News Ltd. All Rights Reserved.